Three Stocks That May Be Priced Below Their Estimated Worth In November 2024
Reviewed by Simply Wall St
As global markets navigate a complex landscape marked by fluctuating earnings reports and economic signals, investors are keenly observing the recent performance of major indices. Despite record highs in technology-focused sectors, caution prevails amid mixed labor data and ongoing manufacturing challenges. In such an environment, identifying stocks that may be undervalued becomes crucial for investors seeking opportunities where market prices do not fully reflect a company's intrinsic worth.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Avant Group (TSE:3836) | ¥2034.00 | ¥3924.24 | 48.2% |
| On the Beach Group (LSE:OTB) | £1.522 | £3.03 | 49.8% |
| SEI Medical (SET:SEI) | THB5.80 | THB11.54 | 49.7% |
| SciDev (ASX:SDV) | A$0.60 | A$1.22 | 51% |
| Laboratorio Reig Jofre (BME:RJF) | €2.88 | €5.74 | 49.8% |
| Alnylam Pharmaceuticals (NasdaqGS:ALNY) | US$273.01 | US$545.05 | 49.9% |
| Shinsung E&GLtd (KOSE:A011930) | ₩1351.00 | ₩2819.33 | 52.1% |
| Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) | CN¥62.62 | CN¥126.89 | 50.6% |
| Orascom Development Holding (SWX:ODHN) | CHF3.90 | CHF7.79 | 49.9% |
| Cellnex Telecom (BME:CLNX) | €32.50 | €64.80 | 49.8% |
Let's dive into some prime choices out of the screener.
Jiayou International LogisticsLtd (SHSE:603871)
Overview: Jiayou International Logistics Co., Ltd, along with its subsidiaries, provides domestic and international multimodal transportation, logistics infrastructure investment and operation, and supply chain trade services, with a market cap of CN¥20.02 billion.
Operations: Jiayou International Logistics Ltd's revenue is derived from domestic and international multimodal transportation, logistics infrastructure investment and operation, and supply chain trade services.
Estimated Discount To Fair Value: 41.2%
Jiayou International Logistics Ltd. is trading at a significant discount, over 20% below its estimated fair value of CNY 35.58. Recent earnings reports show strong performance with net income rising to CNY 1,088.6 million for the nine months ended September 2024, up from CNY 754.75 million the previous year. Despite high non-cash earnings and a dividend not fully covered by free cash flows, forecasted revenue growth outpaces the Chinese market average at 23.5% annually.
- Our earnings growth report unveils the potential for significant increases in Jiayou International LogisticsLtd's future results.
- Dive into the specifics of Jiayou International LogisticsLtd here with our thorough financial health report.
Guangdong Marubi Biotechnology (SHSE:603983)
Overview: Guangdong Marubi Biotechnology Co., Ltd. operates in China, focusing on the research, development, design, production, sale, and service of cosmetics with a market capitalization of CN¥11.91 billion.
Operations: The company generates revenue primarily from its Personal Products segment, amounting to CN¥2.64 billion.
Estimated Discount To Fair Value: 5%
Guangdong Marubi Biotechnology is trading 5% below its estimated fair value of CNY 33.11. Recent earnings reports show net income increased to CNY 238.8 million for the nine months ended September 2024, up from CNY 173.83 million a year ago, with revenue expected to grow at an annual rate of 21.5%, outpacing the Chinese market average of 14%. However, its dividend yield of 1.65% is not well supported by free cash flows.
- Our expertly prepared growth report on Guangdong Marubi Biotechnology implies its future financial outlook may be stronger than recent results.
- Click here and access our complete balance sheet health report to understand the dynamics of Guangdong Marubi Biotechnology.
Shanghai MicroPort Endovascular MedTech (SHSE:688016)
Overview: Shanghai MicroPort Endovascular MedTech Co., Ltd. focuses on the development and manufacturing of minimally invasive medical devices for vascular diseases and has a market cap of approximately CN¥12.54 billion.
Operations: The company's revenue is primarily derived from its Medical Products segment, totaling CN¥1.27 billion.
Estimated Discount To Fair Value: 21.4%
Shanghai MicroPort Endovascular MedTech is trading 21.4% below its fair value estimate of CNY 134.47, with earnings growing significantly over the past year and expected to continue at 20.73% annually. Recent results show net income rose to CNY 553.34 million for the nine months ended September 2024, up from CNY 388.43 million a year ago, despite volatility in share price and dividends not well covered by free cash flows.
- In light of our recent growth report, it seems possible that Shanghai MicroPort Endovascular MedTech's financial performance will exceed current levels.
- Take a closer look at Shanghai MicroPort Endovascular MedTech's balance sheet health here in our report.
Next Steps
- Get an in-depth perspective on all 936 Undervalued Stocks Based On Cash Flows by using our screener here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SHSE:603871
Jiayou International LogisticsLtd
Engages in the provision of domestic and international multimodal transportation, logistics infrastructure investment, and operation and supply chain trade.
Very undervalued with high growth potential.
